C.R. Bard upgraded to Overweight from Neutral at JPMorgan JPMorgan upgraded C.R. Bard based on expectations for a resolution of the Gore patent litigation, a positive outcome in the LEVANT 2 trial, and higher earnings revisions. Price target raised to $116 from $110.
C.R. Bard upgraded to Neutral from Underweight at JPMorgan JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.